Neoantigens Part II: cell therapies

With sparse readouts trickling in, and more data anticipated in 2023, neoantigen-targeted T cell therapies are still looking to adjacent fields for evidence of potential clinical benefit.

The adolescent field is largely divided according to the types of neoantigens companies are targeting, and how they manufacture neoantigen-specific cells. While first-wave players focused on T cells specific for personalized neoantigens, next-gen programs are largely targeting neoantigens shared by many patients, such as KRAS mutations...